Physician profile
Jay S Dalal
NPI 1770627184
$30,813.22
in general payments reported to CMS, 2019-2025
49 companies · $3,207 in 2025
The $3,207 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,178 · 2020: $8,369 · 2021: $5,530 · 2022: $2,674 · 2023: $3,122 · 2024: $2,733 · 2025: $3,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,120 · Food and Beverage: $3,405 · Education: $315 · Long Term Medical Supply Or Device Loan: $167 · Travel and Lodging: $56.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,120.00 |
| Food and Beverage | $3,404.52 |
| Education | $314.94 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Travel and Lodging | $56.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,209.95 | 2019-2025 | |
| Array Biopharma INC | $4,733.81 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $3,059.35 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Janssen Biotech, INC. | $2,929.47 | 2019-2025 | Tecvayli, Carvykti, Rybrevant |
| Karyopharm Therapeutics INC. | $2,250.00 | 2021 | |
| Pfizer INC. | $2,090.74 | 2019-2025 | |
| Tempus Ai, INC | $1,516.04 | 2024 | |
| R-Pharm US LLC | $1,389.00 | 2019 | |
| Myriad Genetic Laboratories, INC. | $1,337.08 | 2022-2024 | Myrisk |
| Seagen INC. | $1,289.10 | 2020-2023 | Padcev |
| Glaxosmithkline, LLC. | $1,150.00 | 2020 | |
| Genentech USA, INC. | $776.29 | 2019-2025 | Kadcyla, Phesgo, Perjeta |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020-2021 | |
| Incyte Corporation | $346.05 | 2019-2025 | Jakafi, Monjuvi |
| Foundation Medicine, INC. | $229.00 | 2022 |
Show all 48 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.